Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 22, 2025Frontiers in PharmacologyOpen Access

Compared with control groups, TXL was associated with lower all-cause mortality, cardiovascular mortality, and incidence of myocardial reinfarction (P < 0.05).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To evaluate the clinical and preclinical effects of Tongxinluo Capsule on acute myocardial infarction and summarize its reported mechanisms of action to inform clinical decision-making.

Does Tongxinluo Capsule improve clinical outcomes and cardiac function in patients with acute myocardial infarction?

Comparison

Tongxinluo Capsule vs control

Design

Systematic review and meta-analysis

Authors

YWYang WuJGJingxue GuoJFJiasai Fan

Discussion

Loading...

Member takes

Overview

TXL may improve AMI outcomes; hypothesis-generating pending high-quality RCTs.

Structured PICO

Does Tongxinluo Capsule improve clinical outcomes and cardiac function in patients with acute myocardial infarction?

P
Population
54 clinical studies pooling 8,649 patients (4,353 in trial group; 4,296 in control group) and 11 animal studies pooling 189 animals (95 in trial group; 94 in control group) with acute myocardial infarction (AMI).
I
Intervention
Tongxinluo Capsule (TXL)
C
Comparator
Control groups
O
Outcome
All-cause mortality, cardiovascular mortality, and incidence of myocardial reinfarctionhard clinical

Tongxinluo Capsule may improve clinical prognosis, cardiac function, and reduce mortality and reinfarction in patients with acute myocardial infarction, though further high-quality RCTs are needed.

Limitations

  • Limitations of the included studies constrain the strength of conclusions

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/6a76b614de5e3adfbdf6c43dhttps://doi.org/10.3389/fphar.2025.1632809
View Full Paper
Ask AI
Bookmark
Share